Results 1 to 10 of about 173,248 (277)

Impact of in-hospital oral beta-blockers initiation on long-term outcomes in ST-elevation myocardial infarction patients with cardiogenic shock [PDF]

open access: yesFrontiers in Medicine
BackgroundEarly revascularization enables ST-elevation myocardial infarction (STEMI) patients with cardiogenic shock (CS) to initiate oral beta-blockers once hemodynamic stability is achieved, but the impact of such initiation on prognosis remains ...
Xiaojin Gao   +20 more
doaj   +2 more sources

Long-Term Effect of Non-Selective Beta-Blockers in Patients With Rheumatoid Arthritis After Myocardial Infarction—A Nationwide Cohort Study

open access: yesFrontiers in Pharmacology, 2021
Objectives: Rheumatoid arthritis (RA) is an independent nontraditional risk factor for incidence of myocardial infarction (MI) and post-MI outcome is impaired in the RA population.
Sheng-Fu Liu   +14 more
doaj   +1 more source

Neuropsychiatric Consequences of Lipophilic Beta-Blockers

open access: yesMedicina, 2021
Beta-blockers are a class of drugs with important benefits in cardiovascular pathology. In this paper, we aim to highlight their adverse and therapeutic effects in the neuropsychiatric field.
Sabina Alexandra Cojocariu   +5 more
doaj   +1 more source

Beta-blockers for hypertension [PDF]

open access: yesCochrane Database of Systematic Reviews, 2017
Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S.   +4 more
openaire   +3 more sources

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction

open access: yesInternational Journal of Cardiology: Heart & Vasculature, 2020
Beta blockers are a recommended therapy in patients with heart failure with reduced ejection fraction(HFrEF). Beta blockers markedly and unequivocally reduce mortality in patients with heart failure with reduced ejection fraction. However, the beneficial
Xizhen Xu, Dao Wen Wang
doaj   +1 more source

The use of beta-blockers before major trauma and posttrauma outcome: A nationwide population-based study

open access: yesJournal of Medical Sciences, 2022
Background: Beta-blockers are widely used for the treatment of arrhythmia, hypertension, and congestive heart failure. Major trauma causes significant blood loss and subsequent tachycardia and hypotension.
Jen-Chun Wang   +5 more
doaj   +1 more source

Association between Incidence of Prescriptions for Alzheimer’s Disease and Beta-Adrenoceptor Antagonists: A Prescription Sequence Symmetry Analysis

open access: yesPharmaceuticals, 2023
Background: Alzheimer’s disease (AD) is the most common cause of dementia, with a growing number of patients worldwide. The association between AD and treatment with drugs targeting the beta-adrenergic receptor is controversial.
Ali Alghamdi   +5 more
doaj   +1 more source

Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment

open access: yesBMC Medicine, 2020
Background Beta-blockers are widely used for many cardiovascular conditions; however, their efficacy in contemporary clinical practice remains uncertain.
Oliver J. Ziff   +6 more
doaj   +1 more source

Die Beta-Adrenerge blokkeermiddels

open access: yesSouth African Family Practice, 1980
No abstract available.
Loubie Walters
doaj   +1 more source

Beta blockers in traumatic brain injury: a systematic review and meta-analysis

open access: yesTrauma Surgery & Acute Care Open, 2023
Background Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Beta blockers have shown promise in improving mortality and functional outcomes after TBI. The aim of this article is to synthesize the available clinical data on
Andrew Chen   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy